The FDA has also become primarily focused on a new way to dispose of these narcotics: through the U.S. mail. Yes, the U.S. mail, the theft of which is today at unprecedented heights.
Since April 2022, the FDA has been fielding comments and developing a program by which the U.S. Postal Service is envisioned to be widely used for patients to mail unused opioids back to drug manufacturers. This would be the case even though many of the same pharmacies providing a pre-paid envelope also have take-back programs.
The FDA’s strong emphasis on promoting a mail-back program since 2022, which it aims to start in 2024, may already have the unintended consequence of cannibalizing other successful disposal efforts and stymying their growth.